Pliant Therapeutics Appoints Minnie Kuo as COO

Pliant Therapeutics ( (PLRX) ) has shared an update.

On December 10, 2025, Pliant Therapeutics appointed Minnie Kuo as Chief Operating Officer. Ms. Kuo, who joined the company in September 2023 as Chief Development Officer, brings over 20 years of experience in clinical development across multiple therapeutic areas. Her appointment is expected to enhance Pliant’s operational capabilities, given her extensive background in leading clinical and business operations at Vir Biotechnology and other prominent firms.

The most recent analyst rating on (PLRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.

Spark’s Take on PLRX Stock

According to Spark, TipRanks’ AI Analyst, PLRX is a Underperform.

Pliant Therapeutics is currently facing substantial financial difficulties, with zero revenue in 2024 and ongoing net losses. These challenges are reflected in the low financial performance score. Technical analysis shows bearish trends but hints at a potential short-term rebound. Valuation remains poor due to a negative P/E ratio and lack of dividends. Additionally, a significant workforce reduction indicates further strategic challenges. Overall, these factors contribute to a low stock score, indicating high risk and limited appeal for potential investors.

To see Spark’s full report on PLRX stock, click here.

More about Pliant Therapeutics

Pliant Therapeutics, Inc. operates in the biotechnology and pharmaceutical industry, focusing on the development of therapies for various therapeutic areas including respiratory, oncology, neurodegenerative, inflammatory, and infectious diseases.

Average Trading Volume: 1,132,300

Technical Sentiment Signal: Sell

Current Market Cap: $75.58M

For a thorough assessment of PLRX stock, go to TipRanks’ Stock Analysis page.